Granulocyte colony-stimulating factor (G-CSF) mediates bone resorption in periodontitis

Hui Yu1,2, Tianyi Zhang3, Haibin Lu2, Qi Ma4, Dong Zhao1, Jiang Sun5* and Zuomin Wang1*

Abstract

Background: Granulocyte colony-stimulating factor (G-CSF) is an important immune factor that mediates bone metabolism by regulating the functions of osteoclasts and osteoblasts. Bone loss is a serious and progressive result of periodontitis. However, the mechanisms underlying the effects of G-CSF on periodontal inflammation have yet not been completely elucidated. Here, we examined whether an anti-G-CSF antibody could inhibit bone resorption in a model of experimental periodontitis and investigated the local expression of G-CSF in periodontal tissues.

Methods: Experimental periodontitis was induced in mice using ligatures. The levels of G-CSF in serum and bone marrow were measured; immunofluorescence was then performed to analyze the localization and expression of G-CSF in periodontal tissues. Mice with periodontitis were administered anti-G-CSF antibody by tail vein injection to assess the inhibition of bone resorption. Three-dimensional reconstruction was performed to measure bone destruction-related parameters via micro-computed tomography analysis. Immunofluorescence staining was used to investigate the presence of osteocalcin-positive osteoblasts; tartrate-resistant acid phosphatase (TRAP) staining was used to observe osteoclast activity in alveolar bone.

Results: The level of G-CSF in serum was significantly elevated in mice with periodontitis. Immunofluorescence analyses showed that G-CSF was mostly expressed in the cell membrane of gingival epithelial cells; this expression was enhanced in the periodontitis group. Additionally, systemic administration of anti-G-CSF antibody significantly inhibited alveolar bone resorption, as evidenced by improvements in bone volume/total volume, bone surface area/bone volume, trabecular thickness, trabecular spacing, and trabecular pattern factor values. Immunofluorescence analysis revealed an enhanced number of osteocalcin-positive osteoblasts, while TRAP staining revealed reduction of osteoclast activity.

Conclusions: G-CSF expression levels were significantly up-regulated in the serum and gingival epithelial cells. Together, anti-G-CSF antibody administration could alleviate alveolar bone resorption, suggesting that G-CSF may be one of the essential immune factors that mediate the bone loss in periodontitis.

Background

Periodontitis is a bacterial infection-driven inflammatory disease in periodontal tissues. Recently, the Global Burden of Disease study (1990–2010) showed that oral conditions remain a substantial public health problem; globally, 796 million people exhibit severe periodontitis, while 267 million people have total tooth loss. Accordingly, severe periodontitis is the sixth most...
characteristic features of periodontitis include the formation of periodontal pockets, as well as attachment loss and alveolar bone resorption; these are irreversible and lead to tooth loss. Alveolar bone resorption is the principal indicator of periodontitis progression [2]. Therefore, the prevention of alveolar bone loss and promotion of bone regeneration are important clinical challenges in the treatment of patients with periodontitis. Despite continuous advancements in periodontology techniques (e.g., subgingival scaling, root planing, and laser treatment), the primary goal of periodontal treatment remains the mechanical removal of biofilms. However, it is difficult to recover the lost bone because of an insufficient understanding of the host immune response [3]. The occurrence of periodontitis requires an interaction between the periodontal microbial biofilm and the host immune response, which leads to alveolar bone loss [4]. Although the plaque biofilm contributes to initial onset of periodontitis, its presence is not essential for periodontitis progression [5]. The concept of “bone immunity” has been proposed by some researchers. This concept suggests that the immune cells and systemic immune systems are closely related and interact with each other; immune system abnormalities may therefore cause changes in bone metabolism [6]. This theory provides a new perspective whereby alveolar bone loss can be controlled and prevented by regulating the local immune response to periodontal inflammation [7].

Immune cells are involved in the maintenance of a healthy periodontal equilibrium. Inflamed periodontal tissues produce various proinflammatory cytokines that participate in osteoclastogenesis and collagen degradation in periodontitis; these include interleukins (e.g., IL-1α, IL-1β, and IL-6), tumor necrosis factor-α, matrix metalloproteinases, and granulocyte colony-stimulating factor (G-CSF) [8, 9]. G-CSF is an important immune factor that participates in neutrophil production, mobilization, survival, and chemotaxis [10]. Neutrophils form the primary defense system in periodontal tissues. Notably, a lack of neutrophil monitoring of bacterial infection is considered the cause of excessive periodontal deterioration [2]. There is some evidence that the level of G-CSF is elevated in the peripheral blood of patients with periodontitis [11]. G-CSF is widely used in clinical treatment of patients with congenital agranulocytosis; 28% of those patients develop osteoporosis after treatment with G-CSF [12]. This clinical phenomenon has also been verified in animal experiments; after long-term treatment with G-CSF, diminished bone mass was associated with significant reduction of mature osteoblasts [13]. Additionally, G-CSF has been reported to mediate osteoblast reduction in an animal model of sepsis [14].

In our previous study, we have found that the level of G-CSF in gingival tissues was markedly increased in the periodontitis group, and the higher expression of G-CSF was correlated with higher infiltration of immune cells, especially with neutrophil infiltration [15]. But, the relationship between G-CSF and periodontal bone loss has not been fully elucidated. So, in this study, we mainly focused on whether G-CSF was one of the key inflammatory factors that mediates bone resorption in periodontitis. To determine the roles of G-CSF in periodontal bone loss, we investigated the localization and expression of G-CSF, as well as the effects of anti-G-CSF antibody administration, in a mouse model of experimental periodontitis.

**Methods**

**Mice**

This study was conducted in accordance with the tenets of the Declaration of Helsinki. All experiments involving studies performed with animals were approved by the Ethics Committee of the Affiliated Zhongshan Hospital of Dalian University (ethics approval number: 2019081503). Eight-week-old specific-pathogen-free C57BL/6 male mice (weight: 20±10 g) were obtained from the Experimental Animal Center of Dalian Medical University (Dalian, China). Male mice were selected because they have better physical health indicators than female mice, which can help to reduce experimental artifacts or problems interpreting the findings. During the experiment, the mice were provided standard laboratory food and water. After the experimental period, the mice were sacrificed following the induction of general anesthesia.

**Establishment of periodontitis model**

After the mice had been adapted to the feeding environment for 1 week, a subset of mice was divided into two groups: control (n=10, without ligature placement) and periodontitis (n=10). For establishment of the periodontitis model: general anesthesia was induced in the mice using intraperitoneal injections of 0.5% pentobarbital sodium (0.3 ml per mouse). Experimental periodontitis was then induced with a 5–0 silk ligature (SA82G, Merck, Ethicon, NJ, USA) around the cervical portion of the maxillary second molar without gingival damage [16]. After 5 weeks of periodontitis modeling, mice were sacrificed to assess the local and systemic expression levels of G-CSF. Another subset of mice was divided into three groups: (1) control (n=6; each mouse did not undergo ligature placement, but received 1.5 μg of control IgG; MAB005, R&D Systems, Minneapolis, MN, USA); (2) periodontitis (n=6; each mouse underwent induction of experimental periodontitis, then received 1.5 μg...
of control IgG); (3) periodontitis + anti-G-CSF (n=6; each mouse underwent induction of experimental peri-
odontitis, then received 1.5 µg of anti-G-CSF antibody; MAB414, R&D Systems). Antibody administration was
performed by tail vein injection at 3-day intervals for 2 weeks. After 5 weeks, the mice were sacrificed to inves-
tigate the effects of anti-G-CSF antibody administration on the loss of bone mass.

Sample collection
Serum extraction: After the induction of anesthesia, 1.5–2 ml blood samples were obtained by the removal of
mouse eyeballs. The blood was incubated at room temperature for 2 h to enable full solidification. It was then
centrifuged at 3000×g for 15 min. The separated serum was quickly transferred to new tubes and stored at -80 °C
for subsequent analysis.

Extraction of bone marrow supernatant: After the induction of euthanasia, mice were placed on a super-
clean platform and soaked in 75% alcohol for 5 min. One set of surgical instruments was used to separate mouse
skin; a second set of surgical instruments was then used to remove the muscle and tendon tissue attached to the
femur. Subsequently, the femur and tibia were extracted; the femoral metaphysis was severed and washed with
1 ml of heparinized phosphate-buffered saline to collect bone marrow. The suspension was centrifuged at 3000×g
for 15 min; the supernatant was then collected and stored at -80 °C for subsequent analysis.

Maxillary sample fixation: Mouse maxillary specimens were fixed in 4% paraformaldehyde for 48 h, then sub-
jected to micro-computed tomography (Inveon™ Multi Modality; Siemens Medical Solutions, Inc., Malvern, PA,
USA) analyses.

Maxillary decalcification: Maxillary specimens were decalcified with ethylene diamine tetraaetacetic acid
(EDTA) disodium salt (E1171, Solarbio, Beijing, China) for 5 weeks. The EDTA decalcifying liquid was changed
at 4-day intervals until each sample could be probed without resistance. All samples were then embedded in
paraffin wax for subsequent analysis.

Enzyme linked immunosorbent assay (ELISA)
The levels of G-CSF in mouse serum and bone mar-
row supernatant were measured using a mouse G-CSF
ELISA kit (EM0086, Fine test, Wuhan, China) in
accordance with the manufacturer’s protocol. Briefly,
a double-antibody sandwich ELISA method was used.
Plates were pre-coated with mouse anti-G-CSF anti-
body. A biotin-conjugated antibody was used as a
detection antibody. The standards, test samples, and
biotin-conjugated detection antibody were then added
to the wells, followed by wash buffer. Horseradish
peroxidase (HRP)-streptavidin was added and unbound
conjugates were removed with wash buffer. Tetrameth-
ylbenzidine (TMB) substrates were used to visualize the
HRP enzymatic reaction, such that HRP interacted with
TMB to produce a blue color that became yellow after
the addition of acidic stop solution. The intensity of the
yellow color was proportional to the amount of G-CSF
in each sample. Optical density values were measured
using a microplate reader (240,351, Bio Tek, Winooski,
VT, USA). The absorbance was set at 450 nm.

Micro-computed tomography scanning and analysis
The computed tomography settings were as follows:
voltage, 80 kV; current, 80 µA; number of images, 1024.
The three-dimensional images were reconstructed
using software provided within the computed tomog-
raphy device (Inveon™ Image Research Place). After
reconstruction, the root bifurcation region in the
second molar was set as the region of interest (a col-
umn-area volume of 0.0058 mm³) and a standardized
threshold was used to analyze the bone destruction-
related parameters (i.e., bone volume/total volume,
bone surface area/bone volume, trabecular thickness,
trabecular number, trabecular spacing, and trabecular
pattern factor).

Histological and immunofluorescence staining
Coronal serial sections (3.5 µm thickness) were affixed
to adhesive slides and stained with hematoxylin and
eosin. Immunofluorescence staining was performed in
accordance with standard protocols. Briefly, conven-
tional dewaxing methods were performed; slides were then
incubated in citrate buffer (pH=6.0, PN5360, G-CLONE,
Beijing, China) that was subjected to microwave heat-
ing for antigen retrieval. Subsequently, endogenous
peroxidases were inactivated by incubation in 3% H₂O₂–
methanol at room temperature for 10 min. Slides were
then blocked with goat serum sealant (KGSP03, Keygen,
Jiangsu, China) at room temperature for 20 min. Immu-
nofluorescence staining was performed with a primary
antibody against G-CSF (1:50 dilution, ab181053, Abcam,
Cambridge, UK) via incubation in a humidified environ-
ment for 2 h at 37°C. Secondary antibody detection was
performed with goat anti-rabbit fluorescein isothio-
cyanate (FITC) (1:50 dilution, 111-095-003, Jackson Immu-
noResearch, West Grove, PA, USA), via incubation in
darkness at 37°C for 1 h. Vectashield mounting medium
with 4′,6-diamidino-2-phenylindole (DAPI) (KGA215,
Keygen) was used for nuclear staining (5 min incubation
at room temperature). Imaging was performed with a
confocal microscope (BX43, Olympus, Tokyo, Japan).
Immunohistochemistry
Paraffin-embedded sections were dewaxed, hydrated, and heat-treated as described in the previous section. An immunohistochemical staining kit (KGSP03, Keygen) with anti-rabbit IgG by streptavidin-peroxidase was used. First, 3% H2O2 was used to inactivate endogenous peroxidases at room temperature for 10 min, followed by blocking with goat serum sealant (KGSP03, Keygen) at room temperature for 10 min. Slides were then incubated with a primary antibody against osteocalcin (OCN) (1:100 dilution, 193876, Abcam) overnight at 4 °C. Secondary antibody detection was performed with anti-rabbit biotin (KGSP03, Keygen), via incubation for 10 min at room temperature. Chain-affinity HRP-labeling was then performed via incubation for 10 min at room temperature. Finally, tissue sections were directly exposed to diaminobenzidine (DAB) chromogen (KGSP03, Keygen) and counterstained with hematoxylin for 5 min. For measurement of integral optical density, three random images were captured from each sample using the 40× objective in a microscope with an attached digital camera (D600, Canon Optical Company, Ltd., Tokyo, Japan). The images were then analyzed with Image-Pro Plus 6.0 software (Media Cybernetics Inc., Bethesda, MD, USA) to quantify the average integral optical density of OCN-positive cells.

Tartrate-resistant acid phosphatase (TRAP) staining
Sections were stained for TRAP activity using a TRAP assay kit (KGA221, Keygen), in accordance with the manufacturer’s instructions. After staining had been performed, multinucleated osteoclasts (adherent to alveolar bone surfaces) were identified using a light microscope (BX53, Olympus). The numbers of TRAP-positive cells were quantified in three random images captured from each sample using the 40× objective in a light microscope.

Statistical analysis
IBM SPSS Statistics, version 22.0 (IBM Corp., Armonk, NY, USA) was used for statistical analysis. All quantitative data are presented as means±standard deviations. Statistical analyses were performed using one-way analysis of variance. Student’s t-test was used to identify statistically significant differences. Values of P<0.05 were considered statistically significant.

Results
Levels of G-CSF in serum and bone marrow
To investigate the levels of G-CSF in our mouse model of periodontitis, we performed ELISA analyses of both serum and bone marrow. Our results showed a significantly greater level of G-CSF in serum from the periodontitis group, compared with the control group (Fig. 1A, P<0.05). The amount of G-CSF in bone marrow tended to be upregulated in the periodontitis group, but this difference was not statistically significant (Fig. 1B, P>0.05).

Localization and expression of G-CSF in periodontal tissue
To evaluate changes in G-CSF localization in periodontal tissue our mouse model of periodontitis, we performed immunofluorescence analysis (Fig. 2). Images of the gingival junctional epithelium were taken by hematoxylin–eosin staining (Fig. 2A, B, E, F) with 20× and
40× objectives, using a light microscope. The results indicated that G-CSF was localized in the membranes of gingival epithelial cells in control mice (Fig. 2C). The membranes of positive cells exhibited green fluorescence (Fig. 2C, G), while the nuclei exhibited blue fluorescence (Fig. 2D, H). The membrane immunoreactivity of G-CSF was enhanced in the periodontitis group (Fig. 2H), compared with the control group (Fig. 2D).
Effects of anti-G-CSF antibody administration on alveolar bone loss

To examine whether anti-G-CSF antibody administration could inhibit bone resorption, we performed micro-computed tomography analysis of bone-related parameters. We captured three-dimensional images of the buccal sides (Fig. 3A, C, E) and palatal sides (Fig. 3B, D, F) of periodontal tissues. Quantitation of these three-dimensional images indicated that the bone volumes of mice in the periodontitis group (Fig. 3C, D) were markedly reduced, compared with those of mice in the control group (Fig. 3A, B). Notably, mice in the periodontitis + anti-G-CSF group showed significant attenuation of alveolar bone resorption (Fig. 3E, F); bone mass loss was also partially alleviated. Mice in the periodontitis + anti-G-CSF group also showed improvements in bone volume/total volume (Fig. 3G), bone surface area/bone volume (Fig. 3H), trabecular thickness (Fig. 3I), trabecular spacing (Fig. 3K), and trabecular pattern factor (Fig. 3L) values, compared with mice in the periodontitis group ($P < 0.05$). However, there were no differences in trabecular number values (Fig. 3J, $P > 0.05$).

Effects of anti-G-CSF antibody administration on osteogenic ability

OCN is synthesized and secreted by osteoblasts; thus, it comprises a specific indicator of bone regeneration and bone formation [6]. Immunohistochemical staining was
performed to analyze the presence of OCN-positive osteoblasts. As shown in Fig. 4A–C, the number of OCN-positive osteoblasts was lower in the periodontitis group (Fig. 4B) than in the periodontitis + anti-G-CSF group (Fig. 4C). The periodontitis + anti-G-CSF group demonstrated an enhanced number of osteoblasts, compared with the periodontitis group (Fig. 4D, P < 0.05).

Effects of anti-G-CSF antibody administration on osteoclasticity
Bone mass can be diminished because of reduced osteogenic capacity, as well as enhanced osteoclast capacity [2]. TRAP is mainly secreted by activated osteoclasts. Here, we conducted TRAP staining to assess changes in osteoclast capacity and bone resorption. Our findings revealed that, compared with the control group (Fig. 5A), bone resorption was significantly worse in the periodontitis group (Fig. 5B); moreover, the periodontitis group exhibited many TRAP-positive multinucleated osteoclasts along the margin of alveolar bone resorption (Fig. 5B). Notably, the periodontitis + anti-G-CSF group (Fig. 5C) exhibited a significantly reduced number of TRAP-positive osteoclasts, compared with the periodontitis group (Fig. 5D, P < 0.05).

Discussion
Alveolar bone is the most active site of bone metabolism and remodeling in the human skeletal system. The most serious damage caused by periodontitis is tooth resorption or loss because of periodontal tissue destruction. Research concerning periodontitis pathogenesis has revealed that plaque biofilm is an initial risk factor for periodontitis; however, some periodontitis-related tissue destruction is caused by the host immune response to the bacteria and toxic factors within the biofilm [4]. Neutrophils form the first defense against bacteria in periodontal tissues. The migration of neutrophils through the junctional epithelium into the
gingival sulcus is a continuous process, such that transmigration is a hallmark of infection [17]. Moreover, periodontitis is a local manifestation of systemic immunoreactivity. Mature neutrophils are stimulated by bacteria and their products such as lipopolysaccharide; they then infiltrate sites of inflammation and phagocytize bacteria under the guidance of cytokines, adhesion molecules, and chemokines. Neutrophils also contribute to periodontal inflammation [17]. Excessive neutrophil reactions to pathogens can cause immune damage. G-CSF is commonly found in multiple tissues and plays a vital role in the immune system [18]. G-CSF is a critical mediator of neutrophil release from the bone marrow, which induces neutrophil mobilization, proliferation, and differentiation [19]; some studies have shown that the level of G-CSF is elevated in peripheral blood from patients with periodontitis [11], but an opposite relationship has been demonstrated in other studies [20]. Furthermore, some adolescent patients with systemic lupus erythematosus have poor periodontal statuses, with higher levels of G-CSF in gingival crevicular fluid and serum [21]. In our previous study, the level of G-CSF in gingival tissues was markedly increased in the periodontitis group [15].

![Quantification of osteoblasts and representative images of immunohistochemical staining](image)

**Fig. 4** Quantification of osteoblasts and representative images of immunohistochemical staining (A to C). The periodontitis + anti-G-CSF group demonstrated an enhanced number of osteoblasts, compared with the periodontitis group (D). The yellow arrow indicates osteoblasts. Data are presented as mean ± SD. *P < 0.05, **P < 0.01; One-way ANOVA with Bonferroni correction.
Yu et al. BMC Oral Health          (2021) 21:299  

study, we found that the level of G-CSF in serum was significantly higher in mice with experimental periodontitis, compared with the control group (Fig. 1A). Also, the level of G-CSF in bone marrow tended to be upregulated, but this difference was not statistically significant (Fig. 1B). Immunofluorescence analyses further demonstrated the localization and expression of G-CSF. Notably, G-CSF was strongly expressed in the membranes of gingival epithelial cells in mice in the periodontitis group (Fig. 2H), compared with mice in the control group (Fig. 2D). Taken together with the previous studies, our findings suggest that G-CSF is a critical immune factor that contributes to the onset of periodontitis.

In the context of periodontitis, the decline in osteoblast function partly occurs because of osteoblast apoptosis, which is mediated by the secretion of G-CSF from bone marrow nucleated cells [22]. Staphylococcus aureus infection has been shown to suppress the osteoblastic cell function and induce progressive bone loss by upregulating the level of G-CSF [23]. Furthermore, G-CSF inhibits the growth of both osteoblasts and osteocytes by

Fig. 5 TRAP staining was used to detect the osteoclasts (A to C). TRAP-positive osteoclasts (red color) were arrayed along alveolar bone surface. Quantitative analysis was performed on the number of TRAP-positive osteoclasts (D). The periodontitis + anti-G-CSF group exhibited a significantly reduced number of TRAP-positive osteoclasts, compared with the periodontitis group. Yellow arrow indicates TRAP-positive osteoclasts. AB: alveolar bone, T: tooth, PL: periodontal ligament. Data are presented as mean ± SD. *P < 0.05, using one-way ANOVA with Bonferroni correction.
upregulating the production of nitric oxide from neutrophils [24]. There were some evidences that G-CSF affects osteoblasts. To the best of our knowledge, there have been few studies concerning the effects of G-CSF on alveolar bone resorption and bone loss in the context of periodontitis. To precisely examine whether the administration of an anti-G-CSF antibody could inhibit bone resorption, we used micro-computed tomography to evaluate the irregular bone loss in the second molar root bifurcation region in our mouse model of periodontitis. The bone volumes of mice in the periodontitis group were markedly reduced (Fig. 3C, D), compared with those of mice in the control group (Fig. 3A, B). Furthermore, bone resorption was significantly inhibited by anti-G-CSF antibody administration (Fig. 3E, F). Our results implied that G-CSF blockage could alleviate alveolar bone resorption and height reduction.

The maintenance of normal bone metabolism includes both formation and destruction of bone. Changes in bone mass are regulated by osteogenic and osteoclastic characteristics. A study have revealed that in G-CSF induced hematopoietic stem progenitor cells mobilization, the expression of osteoblasts and OCN were significantly reduced [25]. Moreover, human osteoblasts treated with recombinant human G-CSF showed slightly lower rates of proliferation [26]. Furthermore, in humans, serum osteocalcin concentration, a specific marker of bone formation, was strongly reduced after 3 days of G-CSF administration [27]. The expression of Runx2, a transcription factor controlling osteoblast function, was dramatically downregulated by G-CSF administration in the bone marrow of mice [28]. OCN is synthesized and secreted by osteoblasts; thus, it comprises a specific indicator of bone regeneration and bone formation. Here, we conducted immunohistochemistry to evaluate changes in OCN during osteogenesis. Our findings are consistent with those of prior studies [13, 14], such that the number of OCN-positive osteoblasts was consistently lower among mice in the periodontitis group (Fig. 4B) than among mice in the periodontitis + anti-G-CSF group (Fig. 4C). These results demonstrated that anti-G-CSF antibody treatment led to improved osteoblast activity and enhanced bone formation. Furthermore, our findings suggest that G-CSF may constitute a crucial immune factor that participates in alveolar bone resorption during periodontitis.

In vitro analyses of human cells have shown that G-CSF can reduce the number and activity of pre-osteoblasts through B-lymphocyte-mediated signaling; G-CSF can also inhibit osteoclast activity through T-lymphocyte-mediated signaling [29]. Notably, the short-term use of G-CSF in children with cancer can affect bone metabolism and contribute to metabolic changes. Specifically, reduced osteoblastic activity and enhanced osteoclastic activity may lead to osteoporosis-related bone pain in these patients [30]. Osteoblasts promote the formation of new bone, while osteoclasts promote bone resorption; these opposing effects can maintain bone remodeling balance. Additionally, osteoclasts are dispensable for hematopoietic progenitor mobilization by G-CSF in mice [31]; short-term G-CSF treatment leads to reduced osteoblast number and osteoclast stimulation [32]. In this study, we used TRAP staining to assess changes in osteoclast capacity and bone resorption in our mouse model of periodontitis. TRAP is mainly secreted by activated osteoclasts. Importantly, we found that the number of TRAP-positive osteoclasts was significantly reduced in the periodontitis + anti-G-CSF group (Fig. 5C). These results suggested that anti-G-CSF antibody treatment could reduce osteoclast activity and alleviate alveolar bone absorption.

Our results suggested that G-CSF may be an important inflammatory factor that mediates periodontitis-related bone loss, although the specific mechanism remains unclear. In a future study, we will perform a detailed investigation of the cellular mechanism of G-CSF-mediated bone loss.

Conclusions
In conclusion, we found that G-CSF was highly expressed in periodontal tissues in a mouse model of periodontitis. Anti-G-CSF antibody treatment significantly inhibited alveolar bone resorption, as evidenced by improvements in bone volume/total volume, bone surface area/bone volume, trabecular thickness, trabecular spacing, and trabecular pattern factor values, as well as by changes in the numbers of cells that exhibited expression of osteocalcin and TRAP. These findings indicate that G-CSF may be one of the essential immune factors that mediate the bone loss in periodontitis. Moreover, the findings constitute new evidence to support novel immune-mediated treatments for bone damage in the context of periodontitis.

Abbreviations
G-CSF: Granulocyte colony stimulating factor; TRAP: Tartrate-resistant acid phosphatase; EDTA: Ethylene diamine tetraacetic acid; ELISA: Enzyme linked immunosorbent assay; HRP: Horseradish peroxidase; TMB: 3,3′-diaminobenzidine; FITC: Fluorescein isothiocyanate; DAPI: 4′,6-diamidino-2-phenylindole; OCN: Osteocalcin; DAB: 3,3′-diaminobenzidine; SD: Standard deviations.

Acknowledgements
Not applicable.

Authors’ contributions
HY designed the study, carried out the data collection and drafted the manuscript; TZ revised the manuscript and gave statistical analysis guidance. HY, HL and QM performed the measurements; DZ gave statistical analysis guidance.
JS gave procedure guidance; ZW guided the whole process of the study. All authors read and approved the final manuscript.

Funding
This study was supported by National Nature Science Foundation of China (No:81870763), Natural Science Foundation of Beijing, China (No:7192073) and Dalian Medical Science Research Project (No:1911095).

Availability of data and materials
All raw data used and analyzed during the current research are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was conducted in accordance with the Declaration of Helsinki. And the study was carried out in compliance with the ARRIVE guidelines 2.0. All experiments involving studies performed with animals were approved according to the Ethics Committee of the Affiliated Zhongshan Hospital of Dalian University (ethics approval number: 2019081503).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Stomatology, Beijing Chao-Yang Hospital, Capital Medical University, 8th Gongti South Road, Beijing, China. 2 Department of Stomatology, Affiliated Zhongshan Hospital of Dalian University, 6th Jiefang Street, Dalian, Liaoning, China. 3 Shenyi Medical University, 382th Wuyi Road, Xinghuaing District, Taiyuan, Shanxi, China. 4 Department of Pathology, Affiliated Zhongshan Hospital of Dalian University, 6th Jiefang Street, Dalian, Liaoning, China. 5 Department of Periodontology, Dalian Stomatological Hospital, 935th Changjiang Road, Dalian, Liaoning, China.

Received: 17 November 2020 Accepted: 30 May 2021
Published online: 12 June 2021

References
1. Kassebaum NJ, Bernabe E, Dahiya M, Bhandari B, Murray CJL, Marcenes W. Global burden of severe periodontitis in 1990–2010: a systematic review and meta-regression. J Dent Res. 2014;93(1):1045–53.
2. Kinnunen E, Gursoy M, Gursoy UK. Periodontitis: a multifaceted disease of tooth-supporting tissues. J Clin Med. 2019;8(9):1135.
3. Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. Nat Rev Microbiol. 2010;8(7):481–90.
4. Tsai C, Tang CY, Tan T, Chen K, Liao K, Liou M. Subgingival microbiota in individuals with severe chronic periodontitis. J Microbiol Immunol Infect. 2018;51(2):226–34.
5. Elmarfi S, Zhou J, Simint HÖ, Könönen E, Gursoy M, Gursoy UK. Regulation of gingival epithelial cytokine response by bacterial cyclic dinucleotides. J Oral Microbiol. 2019;11(1):1538927.
6. Atten JR, Choi Y. Bone versus immune system. Nature. 2000;408(6812):535–6.
7. Meyle J, Dommisch H, Groeger S, Giacaman RA, Costalonga M, Hirschberg M. The innate host response in caries and periodontitis. J Clin Periodontol. 2017;44(12):1215–25.
8. Hajishengallis G, Sahingur SE. Novel inflammatory pathways in periodontitis. Adv Dent Res. 2014;26(1):23–9.
9. Kurugan S, Kantarcı A. Molecular basis for immunohistochemical and inflammatory changes during progression of gingivitis to periodontitis. Periodontol 2000. 2020;2018:26(1):51–67.
10. Mickiew C, Dalgiedzi I, Dapkinus Z, Zvetblis G, Peslakas H, Kaupins A, et al. Construction, purification, and characterization of a homodimeric granulocytic colony-stimulating factor. Mol Biotechnol. 2017;59(9–10):374–84.
11. Queiroz AC, Tabo M Jr, O’Connell PK, Nóbrega PB, Costa PP, Kawata WS, et al. Inflammation markers in healthy and periodontitis patients: a preliminary data screening. Braz Dent J. 2008;19(1):3–8.
12. Dale DC, Bolyard AA, Schwinzer BG, Pracht G, Bonilla MA, Boxer L, et al. The severe chronic neutropenia international registry: 10-year follow-up report. Support Cancer Ther. 2006;3(4):220–31.
13. Christopher MJ, Link DC. Granulocyte colony-stimulating factor induces osteoblast apoptosis and inhibits osteoblast differentiation. J Bone Miner Res. 2008;23(11):1765–74.
14. Terashima A, Okamoto K, Nakashima T, Akira S, Ikuta K, Takayanagi H. Sepsis-induced osteoblast ablation causes immunodeficiency. Immunity. 2016;44(6):1434–43.
15. Zhang Z, Yuan W, Deng J, Wang D, Zhang T, Peng L, et al. Granulocyte colony stimulating factor (G-CSF) regulates neutrophil infiltration and periodontal tissue destruction in an experimental periodontitis. Mol Immunol. 2020;117:110–21.
16. Abe T, Hajishengallis G. Optimization of the ligature-induced periodontitis model in mice. J Immunol Methods. 2013;394(1–2):49–54.
17. Parkos CA. Neutrophil-epithelial interactions: a double-edged sword. Am J Pathol. 2016;186(6):1404–16.
18. Wuerfel W. Treatment with granulocyte colony-stimulating factor in patients with repetitive implantation failures and/or recurrent spontaneous abortions. J Reprod Immunol. 2015;108:123–35.
19. Semerdjii CL, Liu F, Gregory AD, Stumpf K, Link DC. G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity. 2002;17(4):413–23.
20. Elabddeen HRZ, Mustafa M, Ali R, Bolstad A. Cytokine profile in gingival crevicular fluid and plasma of patients with aggressive periodontitis. Acta Odontol Scand. 2017;75(8):616–22.
21. Sete MRC, Carlos JC, Lirajunior R, Boström EA, Sztajnbok FR, Figureiro CM. Clinical, immunological and microbial gingival profile of juvenile systemic lupus erythematosus patients. Lupus. 2019;28(2):189–98.
22. Li S, Chen Y, Qiu L, Qin M. G-CSF indirectly induces apoptosis of osteoblasts during hematopoietic stem cell mobilization. Clin Transl Sci. 2017;10(4):287–91.
23. Hou Y, Qin H, Jiang N, Liu G, Wu H, Bai L, et al. G-CSF partially mediates bone loss induced by Staphylococcus aureus infection in mice. Clin Sci. 2019;133(1):297–308.
24. Zhao J, Zhao Q, Ning R, Shang K, Li C, Ni M, et al. G-CSF inhibits growth of osteoblasts and osteoclasts by upregulating nitric oxide production in neutrophils. J Craniofac Surg. 2019;30(8):e776–80.
25. Li T, Li Q, Li S, Nie Y, Qiu L. Changes of angiotensin I expression in G-CSF induced hematopoietic stem progenitor cells mobilization. Zhonghua Xue Ye Xue Za Zhi. 2015;36(5):418–21.
26. Liu X, Hu X, Cai W, Lu W, Zheng L. Effect of granulocyte-colony stimulating factor on endothelial cells and osteoblasts. Biomed Res Int. 2016;2016:8458721.
27. Takamatsu Y, Simmons PJ, Moore RJ, et al. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood. 1998;92(9):3465–73.
28. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006;124(2):407–21.
29. Li S, Li T, Chen Y, Nie Y, Li C, Liu L, et al. Granulocyte colony-stimulating factor induces osteoblast inhibition by B lymphocytes and osteoclast activation by T lymphocytes during hematopoietic stem/progenitor cell mobilization. Biol Blood Marrow Transplant. 2015;21(8):1384–91.
30. Turhan AB, Binay C, Bor O, Simsek E. The effects of short-term use of granulocyte colony-stimulating factor on bone metabolism in child cancer patients. North Clin Istanb. 2018;5(4):277.
31. Rao M, Supakorndej T, Schmidt AP, Link DC. Osteoclasts are dispensable for hematopoietic progenitor mobilization by granulocyte colony-stimulating factor in mice. Exp Hematol. 2015;43(2):110–4.
32. Li S, Zhao Q, Zou D, Meng H, Xu Z, Li C, et al. A pivotal role of bone remodeling in granulocyte colony stimulating factor induced hematopoietic stem/progenitor cells mobilization. J Cell Physiol. 2013;228(5):1002–9.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.